Lv1
30 积分 2023-12-27 加入
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
28分钟前
待确认
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
1个月前
已完结
China’s increasing flow of innovative assets into big pharma R&D pipelines
1个月前
已完结
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
3个月前
已完结
Inebilizumab for Treatment of IgG4-Related Disease
3个月前
已完结
IgG4-related disease: an update on pathophysiology and implications for clinical care
3个月前
已完结
The old CEACAMs find their new role in tumor immunotherapy
4个月前
已完结
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
4个月前
已完结
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
